The Safety of Vardenafil in Patients Undergoing Cardiac Surgery

Phase 1CompletedNCT01260285

McGuire Research Institute10 enrolled

Overview

The purpose of this study is to evaluate the safety of vardenafil in cardiac surgery patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Ischemia-reperfusion Injury.

Interventions

VardenafilDRUG

10 mg PO once

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * undergoing cardiac surgery Exclusion Criteria: * emergent surgery * recent MI in past 7 days prior to surgery * ejection fraction \< 35% * creatinine \> 2.0 * prior CVA * severe COPD * recent use of nitrates (within past 48 hours prior to surgery) * prior CABG * pregnancy

Locations (1)

McGuire VAMC

Richmond, Virginia, United States

Outcomes

Primary Outcomes

Hypotension

Time frame: approximately 5 days

Secondary Outcomes

Ejection Fraction

Time frame: approximately 5-7 days postop

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.